quetiapine + ziprasidone

Quetiapine + ziprasidone is a combination of two atypical antipsychotic drugs, quetiapine and ziprasidone. Both agents are used individually for the treatment of schizophrenia and bipolar disorder. Quetiapine acts primarily as an antagonist at serotonin 5-HT2A and dopamine D2 receptors, while also affecting other neurotransmitter receptors. Ziprasidone antagonizes dopamine D2 and serotonin 5-HT2A receptors, with additional activity at other serotonergic and adrenergic sites. The combination is not recommended due to a significantly increased risk of QT interval prolongation, which can lead to potentially life-threatening cardiac arrhythmias such as torsades de pointes[1][3][8]. There is no evidence that this specific combination has been developed or approved for any indication; its use together should only occur under exceptional circumstances with close monitoring.